ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,092.02
-0.85%
US Tech 100
21,376.80
-0.95%
다우존스 지수
44,043.11
-1.31%
Bitcoin
97,619.92
1.02%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. AMEX

  6. AEON Biopharma Inc (AEON) 시세

AEON Biopharma Inc

AEON Biopharma Inc (AEON)

AMEX
0.1091
-0.0059
( -5.13% )
업데이트: 01:05:57
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
0.1091
매수가
-
매도가
-
거래량
3,268,671
0.1041 일간 변동폭 0.1115
0.1013 52주 범위 17.17
market_cap
4.361M
전일 종가
0.115
개장가
0.1108
최근 거래 시간
200
@
0.1091
마지막 거래 시간
01:05:56
재정 규모
US$ 349,040
VWAP
0.106784
평균 볼륨(3m)
19,863,160
발행 주식
39,970,693
배당수익률
-
주가수익률
0.18
주당순이익(EPS)
0.6
매출
52.75M
순이익
24.05M

AEON Biopharma Inc 정보

AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-... AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. 더 보기

섹터
Pharmaceutical Preparations
산업
Blank Checks
본부
Wilmington, Delaware, USA
설립됨
2022
AEON Biopharma Inc is listed in the Pharmaceutical Preparations sector of the 아메리카 증권거래소 with ticker AEON. The last closing price for AEON Biopharma was US$0.12. Over the last year, AEON Biopharma shares have traded in a share price range of US$ 0.1013 to US$ 17.17.

AEON Biopharma currently has 39,970,693 shares in issue. The market capitalisation of AEON Biopharma is US$4.60 million. AEON Biopharma has a price to earnings ratio (PE ratio) of 0.18.

AEON 최신 뉴스

추가 뉴스

Form 8-K - Current report
Edgar (US Regulatory)
08 2월 2025
AEON (-5.13%)

Form DEF 14A - Other definitive proxy statements
Edgar (US Regulatory)
24 1월 2025
AEON (-5.13%)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
14 1월 2025
AEON (-5.13%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
07 1월 2025
AEON (-5.13%)

Form 8-K - Current report
Edgar (US Regulatory)
06 1월 2025
AEON (-5.13%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
06 1월 2025
AEON (-5.13%)

Form 8-K - Current report
Edgar (US Regulatory)
21 12월 2024
AEON (-5.13%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
15 11월 2024
AEON (-5.13%)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Edgar (US Regulatory)
14 11월 2024
AEON (-5.13%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.022-16.78108314260.13110.13170.103100048620.11633083CS
4-0.0247-18.46038863980.13380.15310.10362729160.12664677CS
12-0.4532-80.59754579410.56230.90.1013198631600.1727562CS
26-0.8909-89.0911.60510.101385676570.17973077CS
52-9.8909-98.9091017.170.101347245660.42443017CS
156-10.0309-98.924063116410.1417.170.101330069570.46601085CS
260-10.0309-98.924063116410.1417.170.101330069570.46601085CS

AEON - Frequently Asked Questions (FAQ)

What is the current AEON Biopharma share price?
The current share price of AEON Biopharma is US$ 0.1091
How many AEON Biopharma shares are in issue?
AEON Biopharma has 39,970,693 shares in issue
What is the market cap of AEON Biopharma?
The market capitalisation of AEON Biopharma is USD 4.6M
What is the 1 year trading range for AEON Biopharma share price?
AEON Biopharma has traded in the range of US$ 0.1013 to US$ 17.17 during the past year
What is the PE ratio of AEON Biopharma?
The price to earnings ratio of AEON Biopharma is 0.18
What is the cash to sales ratio of AEON Biopharma?
The cash to sales ratio of AEON Biopharma is 0.08
What is the reporting currency for AEON Biopharma?
AEON Biopharma reports financial results in USD
What is the latest annual turnover for AEON Biopharma?
The latest annual turnover of AEON Biopharma is USD 52.75M
What is the latest annual profit for AEON Biopharma?
The latest annual profit of AEON Biopharma is USD 24.05M
What is the registered address of AEON Biopharma?
The registered address for AEON Biopharma is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
Which industry sector does AEON Biopharma operate in?
AEON Biopharma operates in the BLANK CHECKS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
OBEObsidian Energy Ltd
US$ 6.1008
(11.94%)
527.06k
NNVCNanoViricides Inc
US$ 1.525
(11.31%)
320.27k
GOROGold Resource Corporation
US$ 0.3979
(10.93%)
1.1M
KOLDProShares UltraShort Bloomberg Natural Gas
US$ 21.90
(10.61%)
6.14M
BFIXBuild Bond Innovation ETF
US$ 27.36
(9.93%)
35
DDCDDC Enterprise Limited
US$ 0.2001
(-15.75%)
382.25k
ROBNT Rex 2X Long HOOD Daily Target ETF
US$ 26.09
(-12.95%)
299.6k
CVNYYieldmax Cvna Option Income Strategy ETF
US$ 49.72
(-12.16%)
24.19k
PLTYYieldmax Pltr Option Income Strategy ETF
US$ 76.86
(-11.63%)
182.16k
BOILProShares Ultra Bloomberg Natural Gas New
US$ 86.1903
(-10.07%)
958.31k
FXIiShares China Large Cap
US$ 35.655
(1.73%)
36.41M
KWEBKraneShares CSI China Internet
US$ 35.595
(1.76%)
27.06M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 31.04
(-1.37%)
25.62M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 17.65
(1.20%)
22.53M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.9399
(5.56%)
21.35M

AEON Discussion

게시물 보기
tw0122 tw0122 1 월 전
All out at .19 good luck nice bottoming 
👍️0
glenn1919 glenn1919 1 월 전
AEON.......................................@.20 .........................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783







............thx.......................
👍️0
tw0122 tw0122 1 월 전
Bounce bounce break .14 see .20
At .13
👍️0
Backstabbed Backstabbed 1 월 전
$AEON - 2 filings released AH! SC-13G
👍️0
0210 0210 1 월 전
93m shs traded = 50m buys + 8m(?) vs. 35m sells: https://ih.advfn.com/stock-market/AMEX/aeon-biopharma-AEON/trades
👍️0
0210 0210 1 월 전
new lows still, hah! hmmm.....interesting AEON teens & twenties.
👍️0
0210 0210 1 월 전
aeon aeON AEON https://www.benzinga.com/news/25/01/42821213/why-aeon-biopharma-stock-is-down-65-today
👍️0
0210 0210 1 월 전
A/S 500m O/S 40m Float 10m. 70m traded so far today. buys > sells. hmmm....
👍️0
0210 0210 1 월 전
AEON 19-20cents way below all-time VWAPs and 50cents $20m new offering price!? hmmm....chap 11 pps? lolol.
👍️0
ErnieBilco ErnieBilco 1 월 전
Offering meltdown TIME TO BUY
👍️0
glenn1919 glenn1919 4 월 전
AEON............................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 월 전
AEON new 52=week low
👍️0
willlbone willlbone 7 월 전
Dilution.
👍️0
glenn1919 glenn1919 7 월 전
AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 월 전
AEON under $3
👍️0
glenn1919 glenn1919 7 월 전
AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
DewDiligence DewDiligence 7 월 전
AEON repositions ABP-450 as_a potential Botox biosimilar:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html

AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.

This looks like another instance of Zebra’s Law.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
Monksdream Monksdream 8 월 전
AEON new 52 week low
👍️0
Monksdream Monksdream 8 월 전
AEON new 52 week low
👍️0
DewDiligence DewDiligence 9 월 전
AEON—>55% workforce reduction—ABP-450 clinical development suspended:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs. AEON is all but insolvent—see #msg-174417740.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
DewDiligence DewDiligence 9 월 전
AEON has a liquidity problem—1Q24 results:

https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

No CC.
👍️0
DewDiligence DewDiligence 9 월 전
AEON plows on despite setbacks:

https://www.globenewswire.com/news-release/2024/05/09/2878729/0/en/AEON-Biopharma-Provides-Update-on-Development-Pipeline.html
👍️0
Monksdream Monksdream 10 월 전
AEON new 52+ week low
👍️0
DewDiligence DewDiligence 10 월 전
AEON—(-53%)—reports failed phase-2 in migraine prevention:

https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 11 월 전
Dilution from the redemption of warrants:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
👍️0
trglaa trglaa 11 월 전
What happened here today?
👍️0
DewDiligence DewDiligence 11 월 전
AEON 4Q23 financials:

https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
👍️0
DewDiligence DewDiligence 11 월 전
AEON updates plans for migraine program:

https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html
👍️0
DewDiligence DewDiligence 11 월 전
AEON sells $15M of convertible debt to_supplier, Daewoong:

https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
👍️0
DewDiligence DewDiligence 1 년 전
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

The above PR also includes preclinical data for ABP-450 in PTSD (!?).

AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
👍️0
DewDiligence DewDiligence 1 년 전
AEON needs to raise cash very soon:

https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023. No quarterly CC.
👍️0
DewDiligence DewDiligence 1 년 전
AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance… Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 1 년 전
AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
👍️0
trglaa trglaa 1 년 전
Nice run today.
👍️0
DewDiligence DewDiligence 1 년 전
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

See #msg-172274963 for related info.
👍️0
DewDiligence DewDiligence 2 년 전
AEON's initial press release:

https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
👍️0
TESLA777 TESLA777 2 년 전
$AEON This is the one Im watching/trading tomorrow....GLTY......
👍️0
DewDiligence DewDiligence 2 년 전
AEON’s corporate slide presentation:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
👍️0
DewDiligence DewDiligence 2 년 전
AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
👍️0
DewDiligence DewDiligence 2 년 전
AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:

https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
👍️0

최근 히스토리

AMEX
AEON
AEON Biopharma
LSE
CEMX
Ish Msci Em Cg
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지